The probability of technical and regulatory success (PTRS) in drug development is around 8%1. The highest impact is the 36% probability of success in phase 2, impacted by limited efficacy. To increase efficacy success and thereby patient health and commercial outcomes, pharma must improve the accuracy and speed of decisions by enabling evidence generation on disease and treatment at speed and at scale.
